Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Down 22.1% in May

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) saw a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 2,960,000 shares, a decline of 22.1% from the April 30th total of 3,800,000 shares. Approximately 6.2% of the shares of the stock are sold short. Based on an average daily volume of 2,690,000 shares, the short-interest ratio is presently 1.1 days.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on CKPT shares. D. Boral Capital reaffirmed a "buy" rating and issued a $4.80 target price on shares of Checkpoint Therapeutics in a research report on Monday, March 31st. Lake Street Capital reissued a "hold" rating and issued a $4.10 target price (down from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th. Finally, HC Wainwright reiterated a "neutral" rating and issued a $4.10 price target on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th.

Insider Transactions at Checkpoint Therapeutics

In related news, CFO William Garrett Gray sold 12,322 shares of the business's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $4.05, for a total transaction of $49,904.10. Following the transaction, the chief financial officer now owns 1,446,322 shares of the company's stock, valued at approximately $5,857,604.10. The trade was a 0.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO James F. Oliviero III sold 15,090 shares of the business's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $4.04, for a total transaction of $60,963.60. Following the completion of the sale, the chief executive officer now directly owns 3,759,929 shares in the company, valued at $15,190,113.16. This trade represents a 0.40% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company's stock.

Institutional Trading of Checkpoint Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CKPT. SBI Securities Co. Ltd. purchased a new stake in shares of Checkpoint Therapeutics during the fourth quarter valued at approximately $32,000. Northern Trust Corp raised its position in shares of Checkpoint Therapeutics by 16.4% in the 4th quarter. Northern Trust Corp now owns 72,563 shares of the company's stock worth $232,000 after purchasing an additional 10,232 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Checkpoint Therapeutics by 157.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company's stock worth $34,000 after purchasing an additional 6,486 shares during the last quarter. Virtu Financial LLC raised its position in shares of Checkpoint Therapeutics by 180.5% in the 4th quarter. Virtu Financial LLC now owns 38,157 shares of the company's stock worth $122,000 after purchasing an additional 24,552 shares during the last quarter. Finally, Stifel Financial Corp bought a new stake in Checkpoint Therapeutics in the 4th quarter worth about $32,000. Hedge funds and other institutional investors own 22.00% of the company's stock.

Checkpoint Therapeutics Price Performance

CKPT remained flat at $4.26 during mid-day trading on Tuesday. The firm has a fifty day moving average price of $4.10 and a 200-day moving average price of $3.68. The firm has a market capitalization of $370.71 million, a P/E ratio of -2.32 and a beta of 1.18. Checkpoint Therapeutics has a twelve month low of $1.80 and a twelve month high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.09). As a group, analysts anticipate that Checkpoint Therapeutics will post -0.94 earnings per share for the current fiscal year.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.